OTCMKTS:STDAF STADA Arzneimittel Aktiengesellschaft (STDAF) Stock Price, News & Analysis $110.42 0.00 (0.00%) As of 10/24/2022 Add Compare Share Share Stock Analysis Stock Analysis About STADA Arzneimittel Aktiengesellschaft Stock (OTCMKTS:STDAF) Get STDAF alerts:Sign Up Key Stats Today's Range$110.42▼$110.4250-Day Range$110.42▼$110.4252-Week Range$75.15▼$115.00VolumeN/AAverage Volume180 shsMarket Capitalization$6.88 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview STADA Arzneimittel Aktiengesellschaft is a German pharmaceutical company headquartered in Bad Vilbel, Germany. Founded in 1895, the company develops, manufactures and markets medicines and healthcare products for patients, healthcare professionals and consumers. STADA’s business is organized around three main areas: generics, specialty pharmaceuticals and consumer healthcare. Its portfolio includes prescription medicines, branded generics, biosimilars and nonprescription products addressing areas such as pain, respiratory health, dermatology, women’s health and gastrointestinal care. Consumer brands associated with STADA include Grippostad, Ladival, Hoggar Night and Silomat, although product availability varies by market. The company serves markets across Europe and has operations and commercial activities in numerous countries worldwide. STADA’s products are distributed through pharmacies, hospitals, healthcare providers and retail channels. Peter Goldschmidt has served as the company’s chief executive officer since 2022.AI Generated. May Contain Errors. Read More Receive STDAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for STADA Arzneimittel Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STDAF Stock News HeadlinesStada Arzneimittel AG Registered Shares (STDAF)April 9, 2026 | nasdaq.comKPLUY K+S AktiengesellschaftJanuary 10, 2024 | seekingalpha.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 11 at 1:00 AM | Stansberry Research (Ad)KPLUY K+S AktiengesellschaftJanuary 10, 2024 | seekingalpha.comSTADA Arzneimittel AG V (SAZA)July 21, 2023 | investing.comCBI hired 'toxic' staff and failed to sack offendersMay 30, 2023 | bbc.co.ukSartorius Aktiengesellschaft 2022 Q4 - Results - Earnings Call PresentationJanuary 28, 2023 | seekingalpha.comSee More Headlines STDAF Stock Analysis - Frequently Asked Questions How have STDAF shares performed this year? STADA Arzneimittel Aktiengesellschaft's stock was trading at $110.42 at the beginning of the year. Since then, STDAF stock has increased by 0.0% and is now trading at $110.42. How do I buy shares of STADA Arzneimittel Aktiengesellschaft? Shares of STDAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:STDAF Previous SymbolNASDAQ:STDAF CIKN/A Webwww.stada.com Phone(496) 101-6030Fax49-61-0160-3259Employees12,500Year Founded1895Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.23 Current Ratio1.54 Quick Ratio0.99 Sales & Book Value Annual Sales$3.84 billion Price / Sales1.79 Cash Flow$11.12 per share Price / Cash Flow9.93 Book Value$23.11 per share Price / Book4.78Miscellaneous Outstanding Shares62,342,000Free FloatN/AMarket Cap$6.88 billion OptionableNot Optionable Beta0.38 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:STDAF) was last updated on 10/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding STADA Arzneimittel Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share STADA Arzneimittel Aktiengesellschaft With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
